Grant: Collaborative Health Research Projects
University of Toronto
$96,467.00
Automated assays of gap junction functions and screening of drugs for rescuing conduction in heart tissues
EF 2015-16
Résumé
Sudden cardiac death (SCD) accounts for up to 50% of lives lost from heart disease. The major causes of SCD are genetic
problems (present from birth) and ischemic heart disease resulting from poor lifestyle/obesity, both causing life-threatening
irregular beating of the heart (arrhythmias). We are interested in the genetic causes of the lethal arrhythmias and how they
can be treated. Often the genetic causes of SCD result in changes to gap junctions, which are specialized channels that
allow for communication between heart cells and facilitate coordinated contraction of the heart. Discovery of new
therapeutics for this condition is challenging since measuring changes to (and rescue of) gap junctions is technically difficult.
We have previously devised and published novel methods to measure gap junction activity and have shown how gap
junctions are modified with disease. Our automated system injects a small fluorescent dye into individual cardiomyocytes,
and follows the spread of the dye to measure gap junction function. In this project, we will further develop our system to
perform microinjection in a 96-well plate configuration, allowing us to screen and test many drug compounds for their ability
to correct the disease. Additionally, we will devise a new assay based on calcium movement between cells to validate and
correlate our results, also in a 96-well format. Any potential therapeutics identified will be tested in two human cardiomyocyte
models of sudden cardiac death, showing if the drugs are highly likely to work in patients. Most of the drugs we will test are
already approved by regulatory agencies, ensuring rapid translation to patient care. In summary, our work will devise new
and novel techniques for measuring heart function and deliver new therapies to patients with this prevalent disease.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
478469-2015
Name nom
Sun, Yu
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
96467
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Automated assays of gap junction functions and screening of drugs for rescuing conduction in heart tissues
Keyword
NSERC
Application summary
Sudden cardiac death (SCD) accounts for up to 50% of lives lost from heart disease. The major causes of SCD are genetic
problems (present from birth) and ischemic heart disease resulting from poor lifestyle/obesity, both causing life-threatening
irregular beating of the heart (arrhythmias). We are interested in the genetic causes of the lethal arrhythmias and how they
can be treated. Often the genetic causes of SCD result in changes to gap junctions, which are specialized channels that
allow for communication between heart cells and facilitate coordinated contraction of the heart. Discovery of new
therapeutics for this condition is challenging since measuring changes to (and rescue of) gap junctions is technically difficult.
We have previously devised and published novel methods to measure gap junction activity and have shown how gap
junctions are modified with disease. Our automated system injects a small fluorescent dye into individual cardiomyocytes,
and follows the spread of the dye to measure gap junction function. In this project, we will further develop our system to
perform microinjection in a 96-well plate configuration, allowing us to screen and test many drug compounds for their ability
to correct the disease. Additionally, we will devise a new assay based on calcium movement between cells to validate and
correlate our results, also in a 96-well format. Any potential therapeutics identified will be tested in two human cardiomyocyte
models of sudden cardiac death, showing if the drugs are highly likely to work in patients. Most of the drugs we will test are
already approved by regulatory agencies, ensuring rapid translation to patient care. In summary, our work will devise new
and novel techniques for measuring heart function and deliver new therapies to patients with this prevalent disease.